

Biosketch



Chunchen Wu, Ph.D.

Associate Research Fellow
Department of Laboratory Medicine,
Maternal and Child Health Hospital of Hubei Province,
Tongji Medical College
Huazhong University of Science and Technology
Luoyu Road No.745, Wuhan 430071, China
Phone: 0086-13886184095
email: chunchen_wu@126.com

Studied clinical medicine in Medical School of Wuhan University, Wuhan, China. She received her Ph.D. in Wuhan Institute of Virology, Chinese Academy of Sciences (CAS), Wuhan, China in 2010. She visited and studied in the Institute of Virology, Essen, Germany for one year in 2010. She worked in Wuhan Institute of Virology, CAS till 2019. In 2019, she moved to Department of Laboratory Medicine, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology and worked as an associate Research Fellow there.

Her research is focused on molecular virology and the pathogenesis of hepatitis virus. She found some important clinical HBV mutations can interfere with HBV life cycle and host immune responses. She is also studying the common infectious diseases of women and children caused by virus, such as enterovirus and some common types of viruses that cause respiratory infections in infants and young children.

Research Project Funded by:

The National Basic Research Priorities Program of China (2012CB519001)
The National Natural Science Foundation of China (31200699, 31770681)
The Youth Innovation Promotion Association of CAS (No.201603)

Selected Publications:

1. Li Y[#], Shi J[#], Xia J[#], Duan J, Chen L, Yu X, Lan W, Ma Q, Wu X, Yuan Y, Gong L, Yang X*, Gao H*, **Wu C***. Asymptomatic and Symptomatic Patients with Non-severe Coronavirus Disease (COVID-19) Have Similar Clinical Features and Virological Courses: A Retrospective Single Center Study. (2020); *Front. Microbiol.* 11:1570. (IF: 4.235)
2. **Wu C**, Yang W, Wu X, Zhang T, Zhao Y, Ren W*, Xia J*. Clinical Manifestation and Laboratory Characteristics of SARS-CoV-2 Infection in Pregnant Women. (2020); *Virolog Sin.* 35(3):305-310. (IF:3.242)
3. **Wu C**, Wu X, Xia J*. Hepatitis E virus infection during pregnancy. (2020); *Virolog J.* 17(1):73. (IF: 2.579)
4. Yao Y, Yang B, Chen Y, Wang H, Hu X, Zhou Y, Gao X, Lu M, Niu J, Wen Z, **Wu C***, Chen X*. RNA-Binding

Motif Protein 24 (RBM24) Is Involved in pgRNA Packaging by Mediating Interaction between HBV Polymerase and the Epsilon Element. (2019); *J Virol.* 93(6). pii: e02161-18. (IF: 4.501)

5. Yuan Y, Zhao K, Yao Y, Liu C, Chen Y, Li J, Wang Y, Pei R, Chen J, Hu X, Zhou Y, **Wu C***, Chen X*. HDAC11 restricts HBV replication through epigenetic repression of cccDNA transcription. (2019); *Antiviral Res.* 172:104619. (IF: 4.101)

6. **Wu C**, Li B, Zhang X, Zhao K, Chen Y, Yuan Y, Liu Y, Chen R, Xu D, Chen X, Lu M*. Complementation of Wild-Type and Drug-Resistant Hepatitis B Virus Genomes to Maintain Viral Replication and Rescue Virion Production under Nucleos(t)ide Analogs. (2019); *Virol Sin.* 34(4):377-385. (IF: 3.242)

7. Zhao K, Liu S, Chen Y, Yao Y, Zhou M, Yuan Y, Wang Y, Pei R, Chen J, Hu X, Zhou Y, Zhao H, Lu M, **Wu C***, Chen X*. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B. (2018); *Emerg Microbes Infect.* 7(1):186. (IF: 5.776)

8. Yao Y, Yang B, Cao H, Zhao K, Yuan Y, Chen Y, Zhang Z, Wang Y, Pei R, Chen J, Hu X, Zhou Y, Lu M, **Wu C***, Chen X*. RBM24 stabilizes hepatitis B virus pregenomic RNA but inhibits core protein translation by targeting the terminal redundancy sequence. (2018); *Emerg Microbes Infect.* 7(1):86. (IF: 5.776)

9. Kang Y#, Li F#, Guo H#, Yang S, Zhang Y, Zhu H, Wang J, Mao R, Qin Y, Xu J, Chen X, **Wu C***, Zhang J*. Amino acid substitutions Q129N and T131N/M133T in hepatitis B surface antigen (HBsAg) interfere with the immunogenicity of the corresponding HBsAg or viral replication ability. (2018); *Virus Res.* 257:33-39. (IF: 2.934)

10. **Wu CC**, Chen YS, Cao L, Chen XW, Lu MJ. Hepatitis B virus infection: Defective surface antigen expression and pathogenesis. (2018); *World J Gastroenterol.* 24(31):3488-3499. (IF: 3.665)

11. Zhao K, **Wu C***, Yao Y, Cao L, Zhang Z, Yuan Y, Wang Y, Pei R, Chen J, Hu X, Zhou Y, Lu M, Chen X. Ceruloplasmin inhibits the production of extracellular hepatitis B virions by targeting its middle surface protein. (2017); *J Gen Virol.* 98(6):1410-1421. (IF: 3.376)

12. Zhou M, Zhao K, Yao Y, Yuan Y, Pei R, Wang Y, Chen J, Hu X, Zhou Y, Chen X, **Wu C***. Productive HBV infection of well-differentiated, hNTCP-expressing human hepatoma-derived (Huh7) cells. (2017); *Virol Sin.* 32(6):465-475. (IF: 3.242)

13. Li S, Zhao K, Liu S, **Wu C***, Yao Y, Cao L, Hu X, Zhou Y, Wang Y, Pei R, Lu M, Chen X. HBsAg sT123N mutation induces stronger antibody responses specific to HBsAg and HBcAg and influences in vivo HBsAg clearance. (2017); *Virus Res.* 210:119-125. (IF: 2.934)

Research Group

Staffs:

Jianbo Xia

Ming Lei

Yaqi Zhu

Hao Bi

Xiaoxue Wu

MS and MD/PhD Students:

Yingshan Chen

Canyu Liu